Michigan House Bill HB4366

Michigan 2023-2024 Regular Session

• Introduced: 4/11/23
• Refer: 4/11/23

Caption

Health: pharmaceuticals; distribution of naloxone under the administration of opioid antagonist act to any individual; provide for. Amends title & secs. 103 & 107 of 2019 PA 39 (MCL 15.673 & 15.677) & adds sec. 106. TIE BAR WITH: HB 4365'23

Impact

The bill will foster an environment where agencies can more easily purchase, distribute, and possess opioid antagonists, thus broadening the scope of individuals trained to administer these medications. Sections of the bill provide legal protections against civil and criminal liability for those agencies and trained individuals involved in the distribution and administration process, provided their conduct does not equate to gross negligence or willful misconduct. This limitation of liability aims to encourage more extensive participation from agencies by mitigating the fear of legal repercussions.

Summary

House Bill 4366 aims to amend the 2019 Public Act 39, known as the Administration of Opioid Antagonists Act. This legislation seeks to enhance the distribution and administration of opioid antagonists, specifically by allowing certain employees or agents of designated agencies to carry and administer these life-saving medications in designated circumstances. By expanding access to opioid antagonists like naloxone, the bill intends to combat the opioid crisis by ensuring more individuals are equipped to respond in overdose situations.

Contention

Critics may voice concerns regarding the potential abuse of the immunity provisions outlined in the bill, fearing this could lead to cases of negligence being overlooked under the guise of protection for distribution and administration of opioid antagonists. Additionally, stakeholders may debate the adequacy of training provisions that accompany the distribution of these medications, ensuring that individuals equipped to administer them are adequately prepared for the responsibility. Balancing the urgency of addressing the opioid epidemic while maintaining accountability for administering agents remains a pivotal discourse surrounding the bill.